2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007 - 10th Annual

Novel Bioresponsive Nanocarriers for Tumor-Targeted Drug Delivery

Francis C. Szoka

Francis C. Szoka

Professor of Biopharmaceutical Sciences and Pharmaceutical Chemistry
University of California, San Francisco

Dr Cheresh’ disease and research topics include angiogenesis, cell survival, integrins, signal transduction, tumor invasion, and extracellular matrix.

The Cheresh laboratory studies tumor angiogenesis and tumor cell invasion and metastasis. They have developed a number of inhibitors of tumor angiogenesis that are now being tested clinically in cancer patients. Two of these agents, Vitaxin and Celingitide, show promise for late stage cancer patients and appear safe with little or no side effects.

Their basic research efforts primarily deal with the study of molecular mechanisms that regulate tumor cell and endothelial cell survival, migration and invasion. They focus on signaling pathways initiated by extracellular matrix proteins, integrins and growth factor receptors that influence the biology of tumor cells and angiogenic endothelial cells.

Cheresh and his colleagues have a particular interest in alpha V integrins and their ligands and how integrins regulate the epithelial to mesenchymal transition. They previously reported that integrins avb3 and avb5 mediate distinct mechanisms of angiogenesis regulated by the growth factors basic fibroblast growth factor and vascular endothelial cell growth factor, respectively. These pathways are characterized by distinct signaling pathways and differential activation of Raf kinase in endothelial cells.

More recently they have begun to develop small molecule Raf kinase pathway inhibitors that promote endothelial cell apoptosis and serve to disrupt angiogenesis and tumor growth.

Speaking in the special symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment.


View Confimed Speakers

Back to Conferences & Symposia

 
 

Names, and logos of other organizations are the property of those organizations and not of NSTI.
This event is not open to the general public and NSTI reserves the right to refuse admission and participation to any individual.